A new study on the popular weight loss drug Tirzepatide, manufactured by American pharmaceutical company Eli Lilly, has found the drug could dramatically cut the risk of developing type 2 diabetes in obese or overweight people with prediabetes, compared with a placebo.
Tirzepatide is the active ingredient found in Lily's diabetes product Mounjaro and its obesity treatment Zepbound. The drugmaker said the medication drastically cut the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections.
